1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/29/2024 | HALO | Buy Now | Halozyme Therapeutics | $40.37 | 33.76% | TD Cowen | Brendan Smith | → $54 | Initiates | → Outperform | Get Alert |
02/21/2024 | HALO | Buy Now | Halozyme Therapeutics | $40.37 | 78.35% | JMP Securities | Jason Butler | → $72 | Reiterates | Market Outperform → Market Outperform | Get Alert |
02/21/2024 | HALO | Buy Now | Halozyme Therapeutics | $40.37 | 23.85% | HC Wainwright & Co. | Mitchell Kapoor | $48 → $50 | Maintains | Buy | Get Alert |
01/19/2024 | HALO | Buy Now | Halozyme Therapeutics | $40.37 | 23.85% | Benchmark | Robert Wasserman | → $50 | Reiterates | Buy → Buy | Get Alert |
01/19/2024 | HALO | Buy Now | Halozyme Therapeutics | $40.37 | 18.9% | HC Wainwright & Co. | Mitchell Kapoor | → $48 | Reiterates | Buy → Buy | Get Alert |
01/18/2024 | HALO | Buy Now | Halozyme Therapeutics | $40.37 | 78.35% | JMP Securities | Jason Butler | → $72 | Reiterates | Market Outperform → Market Outperform | Get Alert |
01/18/2024 | HALO | Buy Now | Halozyme Therapeutics | $40.37 | -0.92% | Goldman Sachs | Graig Suvannavejh | $45 → $40 | Maintains | Neutral | Get Alert |
01/18/2024 | HALO | Buy Now | Halozyme Therapeutics | $40.37 | 18.9% | HC Wainwright & Co. | Mitchell Kapoor | $61 → $48 | Maintains | Buy | Get Alert |
12/26/2023 | HALO | Buy Now | Halozyme Therapeutics | $40.37 | 46.15% | Morgan Stanley | Vikram Purohit | $61 → $59 | Maintains | Overweight | Get Alert |
10/20/2023 | HALO | Buy Now | Halozyme Therapeutics | $40.37 | 23.85% | Benchmark | Robert Wasserman | → $50 | Reiterates | Buy → Buy | Get Alert |
10/19/2023 | HALO | Buy Now | Halozyme Therapeutics | $40.37 | 51.1% | HC Wainwright & Co. | Mitchell Kapoor | $60 → $61 | Maintains | Buy | Get Alert |
10/09/2023 | HALO | Buy Now | Halozyme Therapeutics | $40.37 | 48.63% | HC Wainwright & Co. | Mitchell Kapoor | → $60 | Reiterates | Buy → Buy | Get Alert |
09/08/2023 | HALO | Buy Now | Halozyme Therapeutics | $40.37 | 48.63% | HC Wainwright & Co. | Mitchell Kapoor | → $60 | Reiterates | Buy → Buy | Get Alert |
08/30/2023 | HALO | Buy Now | Halozyme Therapeutics | $40.37 | 48.63% | HC Wainwright & Co. | Mitchell Kapoor | → $60 | Reiterates | Buy → Buy | Get Alert |
08/15/2023 | HALO | Buy Now | Halozyme Therapeutics | $40.37 | 48.63% | HC Wainwright & Co. | Mitchell Kapoor | $61 → $60 | Maintains | Buy | Get Alert |
08/10/2023 | HALO | Buy Now | Halozyme Therapeutics | $40.37 | 51.1% | Morgan Stanley | Vikram Purohit | $60 → $61 | Maintains | Overweight | Get Alert |
07/24/2023 | HALO | Buy Now | Halozyme Therapeutics | $40.37 | 51.1% | HC Wainwright & Co. | Mitchell Kapoor | → $61 | Initiates | → Buy | Get Alert |
07/24/2023 | HALO | Buy Now | Halozyme Therapeutics | $40.37 | 11.47% | Goldman Sachs | Graig Suvannavejh | $43 → $45 | Downgrade | Buy → Neutral | Get Alert |
05/10/2023 | HALO | Buy Now | Halozyme Therapeutics | $40.37 | 63.49% | JMP Securities | Jason Butler | → $66 | Reiterates | → Market Outperform | Get Alert |
The latest price target for Halozyme Therapeutics (NASDAQ: HALO) was reported by TD Cowen on February 29, 2024. The analyst firm set a price target for $54.00 expecting HALO to rise to within 12 months (a possible 33.76% upside). 22 analyst firms have reported ratings in the last year.
The latest analyst rating for Halozyme Therapeutics (NASDAQ: HALO) was provided by TD Cowen, and Halozyme Therapeutics initiated their outperform rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Halozyme Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Halozyme Therapeutics was filed on February 29, 2024 so you should expect the next rating to be made available sometime around February 28, 2025.
While ratings are subjective and will change, the latest Halozyme Therapeutics (HALO) rating was a initiated with a price target of $0.00 to $54.00. The current price Halozyme Therapeutics (HALO) is trading at is $40.37, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.